| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 08/03/2004 | US6770656 Amine derivatives for the treatment of apoptosis |
| 08/03/2004 | US6770644 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient |
| 08/03/2004 | US6770626 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors |
| 08/03/2004 | US6770295 Once-daily administration form, while maintaining the desired effect on the bladder, indeed gives a significant reduction of the (already low) side-effects, particularly dry mouth |
| 08/03/2004 | CA2136836C Piperidinyl-terminated n-(dihydroxy alkyl)-ethynyl-alanine amides for treatment of hypertension |
| 07/29/2004 | WO2004063221A1 Metastin derivative and use thereof |
| 07/29/2004 | WO2004063202A1 Fused furan compound |
| 07/29/2004 | WO2004062681A1 Herbal compositions for prostate conditions |
| 07/29/2004 | WO2004062666A2 Use of rho-kinase inhibitorrs for treatment of benign prostatic hyperplasia |
| 07/29/2004 | WO2004050629A3 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence |
| 07/29/2004 | WO2004035536A3 Azo compounds for type i phototherapy |
| 07/29/2004 | WO2003094861A3 Bis-benzimidazoles and related compounds as potassium channel modulators |
| 07/29/2004 | WO2003075741A3 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 07/29/2004 | WO2003022123A3 Methods of kidney transplantation utilizing developing nephric tissue |
| 07/29/2004 | WO2002069883A3 Cathecin derivatives as leukocyte elastase inhibitors for treating inflammatory disorders |
| 07/29/2004 | US20040147741 Heptadecapeptide nociceptin opioid receptor modulators; pain relievers; synthesis |
| 07/29/2004 | US20040147724 for diagnosis/treatment of cancer, myeloproliferative disorders, angiogenesis, obesity, osteoporosis, non-insulin dependent diabetes, lipid metabolism disorder, hypercalcemia, hypercholestrolemia; genetic engineering |
| 07/29/2004 | US20040147614 Serotonin receptor antagonist; administering reboxetine; psychological disorders |
| 07/29/2004 | US20040147600 Mixture of drug with insulin; antidiabetic agents |
| 07/29/2004 | US20040147596 Antidiabetic agents; immunology diseases; antiinflammatory agents |
| 07/29/2004 | US20040147570 Substituted 1 and 2-naphthol mannich bases |
| 07/29/2004 | US20040147562 Controlling cell gene expression; moderate cell proliferation; anticancer agents; antiinflammatory agents; cardiovascular disorders; autoimmune disease |
| 07/29/2004 | US20040147558 Synthesis of 3-amino-thalidomide and its enantiomers |
| 07/29/2004 | US20040147551 Competitive binding to estrogen; prevent mnopause syndrome ; anxiolytic agents; antidepressants; benign prostatic hyperplasia; anticancer agents; inflammatory bowel disorders; antiarthritic agents |
| 07/29/2004 | US20040147542 Chemical compounds |
| 07/29/2004 | US20040147525 Antiinflammatory agents; analgesics; antiarthritic agents |
| 07/29/2004 | US20040147512 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/29/2004 | US20040147506 Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome |
| 07/29/2004 | US20040147490 Immunosuppressants |
| 07/29/2004 | US20040147449 For inhibition of vascularization and for cancer therapy |
| 07/29/2004 | US20040147431 Erythropoietin composition |
| 07/29/2004 | US20040146925 for diagnosis and targeted drug delivery for blood cancer and monitoring protein expression or activity of white blood cells in vitro |
| 07/29/2004 | US20040146888 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 07/29/2004 | US20040146591 Solvent extraction, mixing with aqueous solution; drying; sterilization; drugs, food; aging resistance, cognition activators , brain disorders; incontinence; Alzheimer's disease, autism, Parkinson's disease, antiarthritic agents |
| 07/29/2004 | US20040146508 Use of cd25 binding molecules in steroid-resistant patients |
| 07/29/2004 | US20040146504 Anti-IgE vaccines |
| 07/29/2004 | US20040146488 Gene expression of protein with ability to chaperon antigenic peptides of tumor cells to antigen-presenting cells (APCs); selective replication in and killilng of tumor cells; immunotherapy; antimetastasis and anticarcinogenic agents |
| 07/29/2004 | CA2511858A1 Metastin derivative and use thereof |
| 07/28/2004 | EP1440076A1 Silicon compounds |
| 07/28/2004 | EP1440073A1 Pde9 inhibitors for treating cardiovascular disorders |
| 07/28/2004 | EP1440062A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 07/28/2004 | EP1439841A2 Androgen receptor modulators and methods of use thereof |
| 07/28/2004 | EP1439838A1 Macrolides containing pharmaceutical compositions |
| 07/28/2004 | EP1439837A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
| 07/28/2004 | EP1439835A2 Medical compositions for intravesical treatment of bladder cancer |
| 07/28/2004 | EP1439831A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect |
| 07/28/2004 | EP1439819A1 Formulation of an erodible, gastic retentive oral dosage form using in vitro disintegration test data |
| 07/28/2004 | EP1317264B1 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 07/28/2004 | EP1183042B1 Methods for treating diabetes |
| 07/28/2004 | EP1175445B1 Specific antibodies and antibody fragments for tgfbeta1 |
| 07/28/2004 | EP0946174B1 Treatment of urinary incontinence and compositions for use therein |
| 07/28/2004 | EP0931065B1 use of NITRIC ESTER DERIVATIVES IN the treatment of URINARY INCONTINENCE |
| 07/28/2004 | EP0927183B1 Spirocyclic metalloprotease inhibitors |
| 07/28/2004 | EP0823895B1 Fatty acid esters as bioactive compounds |
| 07/28/2004 | CN1516739A Use of HMG fragments as anti-inflammatory agents |
| 07/28/2004 | CN1516698A Arylindenopyridines with PDE inhibiting activity |
| 07/28/2004 | CN1516691A Phenylpyridine carbonyl piperazine derivative |
| 07/28/2004 | CN1516690A Heterocyclic derivatives and medicines |
| 07/28/2004 | CN1516687A 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| 07/28/2004 | CN1516684A Deuterated N-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds |
| 07/28/2004 | CN1516589A N-biphenylcarbonyl-anjd N-phenylpyridylcarbonyl substituted bi-and tricyclic azepines and diazepines as vasopressing agonists |
| 07/28/2004 | CN1516580A Sulfonamides |
| 07/28/2004 | CN1515590A Erythropoietin conjugate |
| 07/28/2004 | CN1515563A Aryl substituted piperazine for curing benign prostatauxe |
| 07/28/2004 | CN1515562A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative |
| 07/28/2004 | CN1515559A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative |
| 07/28/2004 | CN1515556A Intermediate compound for preparing aryl substituted piperazine |
| 07/28/2004 | CN1515554A Intermediate compound for producing 2-amino-6-(2-substituted-4-phenoxy) substituted pyridine compound |
| 07/28/2004 | CN1515319A Induction of cytotoxic T lymphocyte response |
| 07/28/2004 | CN1515256A Application of estrogen antagonist and estrogen excitent for inhibiting pathological disease |
| 07/28/2004 | CN1159440C Mutants of Rb and p53 genes and uses thereof |
| 07/28/2004 | CN1159314C Thiazolidinedione derivs. as antidiabetic agents |
| 07/27/2004 | US6767917 Diuretics; cardiovascular, kidney and brain disorder treatment; antitumor, antiallergen, and antiasthmatic agents |
| 07/27/2004 | US6767910 Triazolo[4,5-d]pyrimidinyl compounds |
| 07/27/2004 | US6767565 Recovering lignans from plants; obtain plant biomass, expose to extraction solvent, separate solid plant material, remove microorganism from extraction solution, recover lignan |
| 07/22/2004 | WO2004061102A1 Cell cycle-controlling protein and utilization thereof |
| 07/22/2004 | WO2004060893A1 Pyrrolopyridine potassium channel openers |
| 07/22/2004 | WO2004060881A1 1,3-benzothiazinone derivatives, process for producing the same and use thereof |
| 07/22/2004 | WO2004060375A1 A method for treating renal failure |
| 07/22/2004 | WO2004039978A3 Human chondroosteomodulin (tig2), production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases |
| 07/22/2004 | WO2004015058A3 Nephritis treatment by gene therapy |
| 07/22/2004 | WO2003087304A3 Tri-substituted heteroaryls and methods of making and using the same |
| 07/22/2004 | WO2003072135A3 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| 07/22/2004 | WO2003070675A3 Substituted 10-aryl-11h-benzo[b]fluorenes and 7-aryl-5,6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors |
| 07/22/2004 | WO2003017919A3 Composition comprising wenguanguo extracts, methods for preparing same and uses therof |
| 07/22/2004 | WO2003014296A3 A group of novel anti-cancer compounds with specific structure |
| 07/22/2004 | US20040143115 e.g., 1-[2-Benzoxazol-2-ylaminomethyl)-piperidin-1-yl]-1-(2-methyl-5phenyl-thiazol4-yl)-methanone; used to treat disorders where an antagonist of a human orexin receptor is required |
| 07/22/2004 | US20040143014 Therapeutic use of alpha-2-delta ligands |
| 07/22/2004 | US20040143003 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 07/22/2004 | US20040142999 Novel compounds and compositions as cathepsin inhibitors |
| 07/22/2004 | US20040142988 Bladder diseases; bone diosrders; central nerevous system diosrders |
| 07/22/2004 | US20040142987 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists |
| 07/22/2004 | US20040142982 Urea derivatives as integrin alpha 4 antagonists |
| 07/22/2004 | US20040142934 treatment of rheumatoid arthritis and/or pain; INHIBIT activity of VEGF receptor tyrosine kinase and VEGF-dependent cell proliferation |
| 07/22/2004 | US20040142932 treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase activity |
| 07/22/2004 | US20040142931 inhibit the tyrosine kinase activity of growth factor receptors such as HER1, HER2, and HER4 |
| 07/22/2004 | US20040142927 Inhibitors of p38 |
| 07/22/2004 | US20040142920 acute or chronic transplant rejection or inflammatory or autoimmune diseases |
| 07/22/2004 | US20040142886 use of vascular endothelial growth factor to enhance smooth muscle cell proliferation and to treat diseases associated with reduced smooth muscle cell proliferation |
| 07/22/2004 | US20040142877 Ligands of the $g(a)v$g(b)6 integrin |